PALLUS Trial

Summary: Evaluated dronedarone versus placebo in high risk patients with permanent atrial fibrillation or atrial flutter. There was an increased cardiovascular death, heart failure and stroke with dronedarone. The trial was terminated early. Dronedarone is not recommended for patients with permanent atrial fibrillation.

Original Publication:

N Engl J Med. 2011 Nov 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19213680

Eponym: Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy trial